Sebastiani Ventures Licenses Artificial Intelligence Technology From Evokai

Author's Avatar
Jun 07, 2022

VANCOUVER, BC / ACCESSWIRE / June 7, 2022 / Sebastiani Ventures Corp. ("Sebastiani" or the "Company") (TSX-V:SBS.H) is pleased to announce that it has entered into a licensing agreement dated effective June 6, 2022 with EvokAI Creative Labs Inc. ("EvokAI") (the "Licensing Agreement"). EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome. EvokAI is at arm's length to the Company.